 |
15 Diseases |  |
9 Trials |
|
9 Trials |  |
174 News |  |
| 123» |
- ProstAtak (aglatimagene besadenovec) / Candel Therap
EXTENDED FOLLOW-UP SHOWS ACCUMULATING BENEFIT FOR PATIENTS TREATED WITH AGLATIMAGENE BESADENOVEC (CAN-2409) +PRODRUG IN COMBINATION WITH STANDARD OF CARE EXTERNAL BEAM RADIATION (EBRT) IN MEN WITH LOCALIZED PROSTATE CANCER: UPDATE FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL (Hall D) - Mar 13, 2026 - Abstract #AUA2026AUA_1106;
P3
Aglatimagene, a replication-defective adenovirus encoding HSV-tk, combined with valacyclovir (prodrug), induces immunogenic cell death. Aglatimagene significantly improved PCa-specific DFS when added to SoC EBRT
- ||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Biomarker, Enrollment change: A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov) - Feb 19, 2026
P2, N=45, Recruiting, Sponsor: Candel Therapeutics, Inc.
Aglatimagene significantly improved PCa-specific DFS when added to SoC EBRT N=30 --> 45
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Biomarker, New P2 trial: A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov) - Jan 12, 2026
P2, N=30, Recruiting, Sponsor: Candel Therapeutics, Inc.
- ProstAtak (aglatimagene besadenovec) / Candel Therap
CAN-2409 with Radiotherapy for Localized Prostate Cancer: A Phase 3, Randomized, Placebo-Controlled Clinical Trial (Costa Del Sol Ballroom) - Nov 2, 2025 - Abstract #PCF2025PCF_72;
- | Review, Journal: The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review. (Pubmed Central) - Oct 18, 2025
OVT appears safe and feasible in pediatric brain tumors, with signals of clinical benefit in selected patients. Larger, controlled trials are needed to clarify its survival impact and define optimal therapeutic strategies.
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC (Poster Hall (Exhibit Halls AB); Virtual) - Oct 3, 2025 - Abstract #SITC2025SITC_851;
P2
(FNIH) by: AbbVie Inc., Amgen Inc., Boehringer-Ingelheim Pharma GmbH & Co. KG., Bristol-Myers Squibb, Celgene Corporation, Genentech Inc, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis Institutes for Biomedical Research, Pfizer Inc., and Sanofi.Trial Registration NCT04495153 ClinicalTrials.govEthics Approval Patients participating in the study provided an IRB-approved informed consent at their participating institutions.
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Phase 3, Randomized, Placebo-Controlled Clinical Trial of CAN-2409 + Prodrug in Combination with Standard of Care Radiation Therapy for Newly Diagnosed, Localized Prostate Cancer with Curative Intent (Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom) - Aug 19, 2025 - Abstract #SITC2025SITC_83;
- ProstAtak (aglatimagene besadenovec) / Candel Therap
CAN-2409 With Continued Immune Checkpoint Inhibitor (ICI) in Patients With Stage III/IV NSCLC With Inadequate Response to ICI (Room 06) - Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_905;
KG., Bristol-Myers Squibb, Celgene Corporation, Genentech Inc, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis Institutes for Biomedical Research, Pfizer Inc., and Sanofi.Trial Registration NCT04495153 ClinicalTrials.govEthics Approval Patients participating in the study provided an IRB-approved informed consent at their participating institutions. Abstract is embargoed at this time.
- |||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion date, Trial primary completion date: PrTK03: Phase 3 Study of ProstAtak (clinicaltrials.gov) - Jul 11, 2025
P3, N=711, Active, not recruiting, Sponsor: Candel Therapeutics, Inc.
Abstract is embargoed at this time. Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Aug 2024
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion: Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 11, 2025
P1, N=12, Completed, Sponsor: Candel Therapeutics, Inc.
Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Aug 2024 Active, not recruiting --> Completed
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion date: Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (clinicaltrials.gov) - Jul 9, 2025
P2, N=187, Active, not recruiting, Sponsor: Candel Therapeutics, Inc.
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409+Prodrug in Combination with Standard of Care External Beam Radiation (EBRT) for Newly Diagnosed Localized Prostate Cancer (Room 24) - Jul 7, 2025 - Abstract #ASTRO2025ASTRO_250;
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer. (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1382;
P3
The addition of CAN-2409 was not associated with significant added toxicity. These data represent the first potentially new therapy for patients with intermediate and high risk PrCa in over 20 years.
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
P1 data, Journal, PD(L)-1 Biomarker, IO biomarker: A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma. (Pubmed Central) - Mar 23, 2025
P1
These findings suggest the opportunity for patient stratification and the potential for more durable antitumor immune responses in future clinical trials of this multimodal standard of care and combined immunotherapy regimen. ClinicalTrials.gov identifier: NCT03576612.
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion, Checkpoint inhibition, IO biomarker: GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas (clinicaltrials.gov) - Feb 14, 2025
P1, N=41, Completed, Sponsor: Candel Therapeutics, Inc.
ClinicalTrials.gov identifier: NCT03576612. Active, not recruiting --> Completed
- | valacyclovir / Generic mfg.
Trial primary completion date: HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM (clinicaltrials.gov) - Nov 25, 2024
P1/2, N=62, Recruiting, Sponsor: The Methodist Hospital Research Institute
Active, not recruiting --> Completed Trial primary completion date: Dec 2023 --> Dec 2025
- | valacyclovir / Generic mfg.
Trial primary completion date: HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM (clinicaltrials.gov) - Nov 25, 2024
P1/2, N=62, Recruiting, Sponsor: David Baskin MD
Trial primary completion date: Dec 2023 --> Dec 2025 Trial primary completion date: Dec 2023 --> Dec 2025
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Impact of Site of CAN-2409 Injection Plus Continued Immune Checkpoint Inhibitor (ICI) In CI-resistant stage III/IV NSCLC (20BC) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1083;
P2
Injection into LT and/or LN is associated with improved survival compared to injection into PM. Administration of CAN-2409 into LT and/or LN is associated with systemic immune activation.
- || Cytovene (ganciclovir) / Roche, ProstAtak (aglatimagene besadenovec) / Candel Therap, Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Clinical, Review, Journal, Gene therapy: Gene therapy for people with hepatocellular carcinoma. (Pubmed Central) - Jun 5, 2024
The impact of gene therapy on adverse events needs to be investigated further. Evidence on the effect of gene therapy on health-related quality of life is lacking.
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI. (Hall A; Poster Bd #: 498) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1508;
P2
Experimental treatment with CAN-2409+valacyclovir in NSCLC pts following an inadequate response to ICI is well tolerated and results in the induction of a cytotoxic and memory circulating T cell response associated with shrinkage of injected and uninjected lesions and a raised tail of the survival curve. mOS of the evaluable population was estimated as 22.0m, markedly longer than the expected mOS of 11.6-14.5m.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, IO biomarker: STOMP: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (clinicaltrials.gov) - Feb 20, 2024
P2, N=57, Completed, Sponsor: The Methodist Hospital Research Institute
mOS of the evaluable population was estimated as 22.0m, markedly longer than the expected mOS of 11.6-14.5m. Active, not recruiting --> Completed
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Enrollment closed, Checkpoint inhibition, IO biomarker: LuTK02: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (clinicaltrials.gov) - Dec 7, 2023
P2, N=90, Active, not recruiting, Sponsor: Candel Therapeutics, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Phase classification: Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma (clinicaltrials.gov) - Nov 21, 2023
P2, N=52, Completed, Sponsor: Candel Therapeutics, Inc.
Recruiting --> Active, not recruiting Phase classification: P2a --> P2
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Journal, Gene therapy: Clinical Efficacy and Safety of AdV-tk Gene Therapy for Patients with Cervical Squamous Intraepithelial Lesion: A Prospective Study. (Pubmed Central) - Oct 22, 2023
Our data indicates that AdV-tk gene therapy has high efficacy and safety in the treatment of cervical SIL among gynecological patients. Our findings provide clinical evidence on the potential promotion and application of AdV-tk in the treatment of cervical SIL, and potentially for cervical cancer, among gynecological patients.
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Neoadjuvant CAN-2409+Prodrug plus chemoradiation for borderline resectable or locally advanced non-metastatic pancreatic adenocarcinoma (PDAC) (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_990;
Our findings provide clinical evidence on the potential promotion and application of AdV-tk in the treatment of cervical SIL, and potentially for cervical cancer, among gynecological patients. CAN-2409+prodrug reduced CA19
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion date: Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 28, 2023
P1, N=12, Active, not recruiting, Sponsor: Candel Therapeutics, Inc.
CAN-2409+prodrug reduced CA19 Trial completion date: May 2022 --> Dec 2024
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial primary completion date, Checkpoint inhibition, IO biomarker: GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas (clinicaltrials.gov) - Jun 5, 2023
P1, N=36, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: May 2022 --> Dec 2024 Trial primary completion date: Apr 2023 --> Oct 2023
- ||||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Clinical, Checkpoint inhibition: #ASCO23 @ASCO #LCSM "CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC" - thrilled to present @StermanDaniel @paulpetertak @OncoAlert Poster Board#138b (Twitter) - Jun 4, 2023
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Preclinical, Journal: Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models. (Pubmed Central) - May 25, 2023
IL-12 synthesis likely depends on interactions with the tumor microenvironment, and it facilitates CAN-2409 cell killing. This dataset provides potential to understand resistance mechanisms and identify potential biomarkers for future studies.
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Enrollment closed, Combination therapy: PaTK02: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - May 15, 2023
P2, N=54, Active, not recruiting, Sponsor: Candel Therapeutics, Inc.
This dataset provides potential to understand resistance mechanisms and identify potential biomarkers for future studies. Recruiting --> Active, not recruiting
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: LuTK02: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (clinicaltrials.gov) - May 10, 2023
P2, N=86, Recruiting, Sponsor: Candel Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Mar 2023 --> Dec 2024
- ||||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Fast track designation, FDA event: Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer https://t.co/0yhMdj50RL (Twitter) - Apr 27, 2023
- ProstAtak (aglatimagene besadenovec) / Candel Therap
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC. (On Demand | Hall A; Poster Bd # 138b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3569;
P2
Exploratory endpoints include evaluation of effects in non-injected lesions, changes in non-target (per RECIST) lesions, tumor growth trajectory, and viral shedding. Clinical trial information: NCT04495153.
- ||||| CAN-3110 / Candel Therap, ProstAtak (aglatimagene besadenovec) / Candel Therap
Clinical: Our President and CEO, Dr. @paulpetertak, and CSO, Dr. @baroneExpMed are in London to discuss how a better future is possible for people diagnosed with #cancer as we develop our investigational viral #immunotherapies, CAN-2409 and CAN-3110, at #Immuno2023. https://t.co/RjBlENohma (Twitter) - Mar 28, 2023
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial primary completion date: Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (clinicaltrials.gov) - Feb 23, 2023
P2, N=187, Active, not recruiting, Sponsor: Candel Therapeutics, Inc.
Clinical trial information: NCT04495153. Trial primary completion date: Mar 2023 --> Dec 2024
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas (clinicaltrials.gov) - Feb 1, 2023
P1, N=36, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial primary completion date: Mar 2023 --> Dec 2024 Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, IO biomarker: STOMP: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (clinicaltrials.gov) - Jan 25, 2023
P2, N=57, Active, not recruiting, Sponsor: The Methodist Hospital Research Institute
Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Apr 2023 Trial primary completion date: Nov 2022 --> Jul 2022
- |||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial primary completion date: PrTK03: Phase 3 Study of ProstAtak (clinicaltrials.gov) - Jan 20, 2023
P3, N=711, Active, not recruiting, Sponsor: Candel Therapeutics, Inc.
Trial primary completion date: Nov 2022 --> Jul 2022 Trial primary completion date: Jun 2023 --> Dec 2024
- ||||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Clinical: Listen below as our CEO, @PaulPeterTak, speaks to our commitment to #patients & how we're developing investigational viral #immunotherapies to save, improve & extend the lives of those impacted by hard-to-treat #cancers: https://t.co/hWcg48Wo0s #CAN2409 #ProstateCancer (Twitter) - Jan 11, 2023
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Efficacy and initial report of Aglatimagene Besadenovec (CAN-2409) antitumor activity in immune checkpoint inadequate responders for NSCLC. (Poster Hall D) - Jan 6, 2023 - Abstract #SIR2023SIR_765;
Direct tumor injection of oncolytic virus in patients with advanced NSCLC and inadequate response to first-line ICI is well tolerated. Early data suggests that CAN-2409 treatment induces immunization against tumor antigens in the injected tumor and un-injected metastases.
- ||||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Clinical: Agreed. Candel Therapeutics presented data on its virtual R&D Day (Dec 6) showing disease control in 77% of patients with progressive NSCLC during ICI treatment after administration of CAN-2409 (in situ vaccination). There was a decrease in size of uninjected tumor in 67%. $CADL (Twitter) - Dec 13, 2022
- ||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: PaTK02: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Dec 9, 2022
P2, N=54, Recruiting, Sponsor: Candel Therapeutics, Inc.
Early data suggests that CAN-2409 treatment induces immunization against tumor antigens in the injected tumor and un-injected metastases. N=38 --> 54 | Trial completion date: Dec 2022 --> Jul 2026 | Trial primary completion date: Dec 2021 --> Dec 2025
- dexamethasone / Generic mfg.
Dexamethasone blunts the efficacy of locally administered immunostimulatory gene therapy in murine glioblastoma () - Nov 30, 2022 - Abstract #DKK2022DKK_2241;
CAN-2409 is a locally administered immunotherapy that uses aglatimagene besadenovec (AdV-tk) with an anti-herpetic prodrug to induce tumor cell death by attracting immune cells to the tumor site. These results support the idea that dexamethasone use should be avoided or limited to the lowest necessary dose.
- Opdivo (nivolumab) / Ono Pharma, BMS, ProstAtak (aglatimagene besadenovec) / Candel Therap
First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma (Hall B2) - Nov 2, 2022 - Abstract #SITC2022SITC_1828;
Additional biomarker analysis and canonical correlation analysis with clinical responses are ongoing. Download figure Open in new tab Download powerpoint Abstract 1477 Figure 1 Schema of treatment and biomarker timepoints Conclusions Combination treatment of CAN-2409/valacyclovir plus nivolumab and SoC induces profound immunological changes and appears to associate with encouraging survival data.
- || Keytruda (pembrolizumab) / Merck (MSD), ProstAtak (aglatimagene besadenovec) / Candel Therap
P2 data, Journal, Checkpoint inhibition, PD(L)-1 Biomarker: A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple Negative Breast Cancer. (Pubmed Central) - Oct 18, 2022
The therapy is a well-tolerated treatment in heavily pretreated mTNBC patients. Early detection of increased effector and effector memory CD8 T cells and myeloids correlate with response and non-response, respectively.
- ProstAtak (aglatimagene besadenovec) / Candel Therap
Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1442;
Conclusions CAN-2409 alters the TME such that newly entering CD8 T cells expand and retain key effector functions while the exhausted CD8 compartment is reinvigorated, likely reducing Treg-mediated suppression. Collectively, these data suggest at least two temporally distinct pathways underpinning CAN-2409 action that overcome cell exhaustion and decreased immune suppression, supporting the rationale for the use of CAN-2409 either as monotherapy or in combination.
- || ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: LuTK02: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC (clinicaltrials.gov) - Sep 29, 2022
P2, N=86, Recruiting, Sponsor: Candel Therapeutics, Inc.
Collectively, these data suggest at least two temporally distinct pathways underpinning CAN-2409 action that overcome cell exhaustion and decreased immune suppression, supporting the rationale for the use of CAN-2409 either as monotherapy or in combination. Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2022 --> Mar 2023
- |||| ProstAtak (aglatimagene besadenovec) / Candel Therap
Charu Aggarwal, MD, MPH, discussed findings from a study of the replication-deficient adenovirus CAN-2409 in advanced non–small cell lung cancer. #NSCLC | @CharuAggarwalMD @PennMedicine https://t.co/LkLpjqWBV8 (Twitter) - Sep 22, 2022
- | Cytovene (ganciclovir) / Roche, ceralasertib (AZD6738) / AstraZeneca, ProstAtak (aglatimagene besadenovec) / Candel Therap
Journal, Oncolytic virus, PD(L)-1 Biomarker, IO biomarker: Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma. (Pubmed Central) - Aug 30, 2022
The expression of tk in transduced cancer cells results in conversion of the pro-drug ganciclovir into a toxic metabolite causing DNA damage, inducing immunogenic cell death and immune activation...We investigated the effects of ATR inhibitor AZD6738 in combination with CAN-2409 in vitro using cytotoxicity, cytokine, and fluorescence-activated cell sorting (FACS) assays in glioma cell lines and in vivo with an orthotopic syngeneic murine glioma model...In a tumor re-challenge, long-term immunity after combination treatment was not improved. Our results suggest that ATR inhibition could amplify CAN-2409's efficacy in glioblastoma through increased DNA damage while having complex immunological ramifications, warranting further studies to determine the ideal conditions for maximized therapeutic benefit.
- | ProstAtak (aglatimagene besadenovec) / Candel Therap
Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas (clinicaltrials.gov) - Aug 8, 2022
P1, N=36, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Our results suggest that ATR inhibition could amplify CAN-2409's efficacy in glioblastoma through increased DNA damage while having complex immunological ramifications, warranting further studies to determine the ideal conditions for maximized therapeutic benefit. Trial completion date: Oct 2022 --> Apr 2023 | Trial primary completion date: Jun 2022 --> Dec 2022